News >

Future Focus on Combinations, Biomarkers in Metastatic NSCLC

Silas Inman @silasinman
Published: Tuesday, Aug 01, 2017

Roy Herbst, MD, PhD

Roy Herbst, MD, PhD
The therapeutic paradigm continues to evolve in advanced non–small cell lung cancer (NSCLC), with increased emphasis being placed on rational combinations and biomarkers in the next few years, according to Roy S. Herbst, MD, PhD, at the 18th Annual International Lung Cancer Congress.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication